» Articles » PMID: 36170269

Saliva Sample for Detection of SARS-CoV-2: A Possible Alternative for Mass Testing

Abstract

Molecular diagnostic testing has played a critical role in the global response to the novel Coronavirus disease (COVID-19) pandemic, since its first outbreak in late 2019. At the inception of the COVID-19 pandemic, nasopharyngeal swab sample analysis for COVID-19 diagnosis using the real-time polymerase chain reaction (RT-PCR) technique was the most widely used. However, due to the high cost and difficulty of sample collection, the number of available sample types for COVID-19 diagnosis is rapidly increasing, as is the COVID-19 diagnostic literature. The use of nasal swabs, saliva, and oral fluids as viable sample options for the effective detection of SARS-CoV-2 has been implemented successfully in different settings since 2020. These alternative sample type provides a plethora of advantages including decreasing the high exposure risk to frontline workers, enhancing the chances of home self-sampling, reducing the cost, and significantly increasing testing capacity. This study sought to ascertain the effectiveness of Saliva samples as an alternative for COVID-19 diagnosis in Nigeria. Demographic data, paired samples of Nasopharyngeal Swab and Drooling Saliva were obtained from 309 consenting individuals aged 8-83 years presenting for COVID-19 testing. All samples were simultaneously assayed for the detection of SARS-CoV-2 RdRp, N, and E genes using the GeneFinder™ COVID-19 Plus RT-PCR test kit. Out of 309 participants, only 299 with valid RT-PCR results comprising 159 (53.2%) males and 140 (46.8%) females were analyzed in this study using the R Statistical package. Among the 299 samples analyzed, 39 (13.0%) had SARS-CoV-2 detected in at least one specimen type. Both swabs and saliva were positive in 20 (51.3%) participants. Ten participants (25.6%) had swab positive/saliva-negative results and 9 participants (23.1%) had saliva positive/swab-negative results. The percentage of positive and negative agreement of the saliva samples with the nasopharyngeal swab were 67% and 97% respectively with positive and negative predictive values as 69% and 96% respectively. The findings indicate that drooling saliva samples have good and comparable diagnostic accuracy to the nasopharyngeal swabs with moderate sensitivities and high specificities.

Citing Articles

Salivary immune responses after COVID-19 vaccination.

Nguyen K, Relja B, Epperson M, Park S, Thornburg N, Costantini V PLoS One. 2024; 19(9):e0307936.

PMID: 39226256 PMC: 11371244. DOI: 10.1371/journal.pone.0307936.


SARS-CoV-2, periodontal pathogens, and host factors: The trinity of oral post-acute sequelae of COVID-19.

Schwartz J, Capistrano K, Gluck J, Hezarkhani A, Naqvi A Rev Med Virol. 2024; 34(3):e2543.

PMID: 38782605 PMC: 11260190. DOI: 10.1002/rmv.2543.


Viruses in saliva from sanctuary chimpanzees (Pan troglodytes) in Republic of Congo and Uganda.

Dunay E, Rukundo J, Atencia R, Cole M, Cantwell A, Emery Thompson M PLoS One. 2023; 18(6):e0288007.

PMID: 37384730 PMC: 10310015. DOI: 10.1371/journal.pone.0288007.

References
1.
Al Suwaidi H, Senok A, Varghese R, Deesi Z, Khansaheb H, Pokasirakath S . Saliva for molecular detection of SARS-CoV-2 in school-age children. Clin Microbiol Infect. 2021; 27(9):1330-1335. PMC: 7894096. DOI: 10.1016/j.cmi.2021.02.009. View

2.
Caulley L, Corsten M, Eapen L, Whelan J, Angel J, Antonation K . Salivary Detection of COVID-19. Ann Intern Med. 2020; 174(1):131-133. PMC: 7470212. DOI: 10.7326/M20-4738. View

3.
Landry M, Criscuolo J, Peaper D . Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. J Clin Virol. 2020; 130:104567. PMC: 7392849. DOI: 10.1016/j.jcv.2020.104567. View

4.
Teo A, Choudhury Y, Tan I, Cher C, Chew S, Yi Wan Z . Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. Sci Rep. 2021; 11(1):3134. PMC: 7862309. DOI: 10.1038/s41598-021-82787-z. View

5.
Nacher M, Mergeay-Fabre M, Blanchet D, Benoit O, Pozl T, Mesphoule P . Prospective Comparison of Saliva and Nasopharyngeal Swab Sampling for Mass Screening for COVID-19. Front Med (Lausanne). 2021; 8:621160. PMC: 7940378. DOI: 10.3389/fmed.2021.621160. View